Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...
The overlap between the work of J&J and Watts has led to a joint push to get women over 40 to focus on eye health. Together, ...
Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback